Lipoprotein(a) Reductions From PCSK9 Inhibition and Major Adverse Cardiovascular Events: Pooled Analysis of Alirocumab Phase 3 Trials

Atherosclerosis - Netherlands
doi 10.1016/j.atherosclerosis.2019.06.896

Related search